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initiation and 65% thereafter for AF and 53% and 59% respectively for VTE. There
was a positive relationship between number of visits during initiation and the
number of subsequent visits (correlation coefficient (r)0.29) and a negative rela-
tionship between number of visits and TTR during both initiation (r-0.3) and
maintenance (r-0.35). CONCLUSIONS: Increasing number of anticoagulation vis-
its was associated with reduced time in range suggesting that despite increased
monitoring some patients fail to stay in range. In addition, patients who require
frequent visits during the initiation phase continue to do so during maintenance,
suggesting that this may be a useful predictor for patients who are likely to be
poorly controlled despite high resource use in the longer term and may hence be
candidates for alternative means of anticoagulation.
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OBJECTIVES: While WHO guidance considers a “misuse” to base national pricing
and reimbursement regulations on ATC/DDD system, in Poland, drugs are reim-
bursed based on costs associated to their corresponding Defined Daily Doses (DDD).
We analysed the group of ACE inhibitors to check whether the observed Prescribed
Daily Doses (PDD) in the Polish setting correspond to DDDs. ACE inhibitors consti-
tute an important therapeutic group in Poland (45 million packs yearly). According
to a recent National Health Fund report, ramipril ranked fifth in terms of total
reimbursement expenditure in 2010 (205 million PLN; 2.4% of the total budget).
METHODS: We used IMS Medical Index report to derive average PDDs for ACE
inhibitors available in Poland. Both monotherapies and fixed-dose combinations
were analysed, irrespective of their prescribed indication. Average Daily Doses
reported for specific preparations were weighted using the actual sales, so that the
results can be interpreted as average PDDs, adjusted to drug use structure. Analysis
is based on year 2010 data. RESULTS: For 10 molecules (benazepril, captopril,
cilazapril, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, tran-
dolapril) the PDDs did not differ more than  0.5 times vs the respective DDDs. On
the contrary, PDD for enalapril and ramipril was significantly higher than DDD (1.8
and 2.9 times the DDD, respectively). This finding is consistent with the prescrip-
tion patterns reported in the German setting – 1.9 and 3.5 times the DDD, respec-
tively (Grimmsmann, Himmel 2010). CONCLUSIONS: New reimbursement law due
to come into force in 2012 may apply a PDD instead of DDD as reference for reim-
bursement, in case DDD is lower than the most frequent dosage. In view of the
above findings, ACE inhibitors should be revised in this aspect. The current practice
of basing limits on DDDs may lead to suboptimal allocation of public funds and
have ultimately negative impact on patients’ access to therapy.
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OBJECTIVES: Evaluation of cardiovascular (CVS) medication prescription in 2010 as
compared to 2005, in relation to age, in the field of primary health care, of Nis region
METHODS: A retrospective study on cardiovascular drugs utilization according to
ATC classification, was conducted on the basis of data received from Central City
Pharmacy Nis, and results were presented in DDD/1000 inhabitants/day RESULTS:
Data analysis confirmed a total increase of CVS medication prescription of 58%
during the research period (251,76:399 DDD/1000inh/d). Thereby, a significantly
higher percentage of prescription was notified among population older than 60 as
compared to younger population (67%: 40%). Except for diuretics, there was an
increasing tendency in all groups of CVS medication prescription in both age
ranges. The highest percentage of prescription was marked in the group of Calcium
antagonist drugs: 95% in patients older than 60 and 84% in younger population.
Beta blockers were prescribed to elderly CVS patients for 29% more than to younger
ones in 2010. The CVS medications prescribed most in the research period were
drugs affecting the renin-angiotensin-aldosterone system (101,5:226,7DDD/
1000inh/d), whereby the increase of usage prevailed among elderly patients
(67%:41%). CONCLUSIONS: The obtained results show a significan increase of CVS
medication prescription, predominantly among elderly patients. The highest per-
centage of prescription was manifested in the group of calcium antagonist drugs as
compared to other medications, in patients of all age groups, whereas no signifi-
cant change in diuretics usage was reflected during the research period.
PCV132
DO ATRIAL FIBRILLATION (AF) PATIENTS GET ORAL ANTICOAGULATION (OAC)
AS GUIDELINES RECOM-MEND? AN ANALYSIS OF GERMAN HEALTH
INSURANCE CLAIMS DATA
Wilke T1, Mueller S1, Groth A2, Verheyen F3, Linder R4, Pfannkuche M5, Breithardt G6,
Bauersachs R7, Maywald U8
1University of Wismar, Wismar, Germany, 2Institute for Pharmacoeconomics and Drug Logistics,
University of Wismar, Wismar, Germany, 3WINEG, Hamburg, Germany, 4Scientific Institute of
Techniker Krankenkasse for Benefit and Efficiency in Health Care, Hamburg, Germany, 5Boeringer
Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany, 6University Clinic Muenster, Muenster,
Germany, 7Klinikum Darmstadt GmbH, Darmstadt, Germany, 8AOK Plus, Dresden, Germany
OBJECTIVES: AF is the most frequent, clinically significant form of arrhythmia
leading to stroke in a substantial proportion of patients. This paper investigates a
possible OAC underuse based on a large German health insurance data set.
METHODS: Based on data from 2 German statutory medical aid funds (2007-2008),
a patient was considered to be in need of OAC if a CHADS2-Score2 without any
OAC contraindication (CI) had been recorded. We used two CI scenarios; 1) a more
extensive CI list based on the German Summary of product characteristics, and 2)
a more limited list based on latest publications. In our day-specific analysis cover-
ing 2008, we classified each observed day into one of the following 3 categories:
OAC use: day covered by OAC prescription (daily required dose defined by daily
defined dose (DDD) or within a 180-days grace-period after consumption of last
prescription); and Uncertain OAC use: OAC prescription in 2008, but the day was
outside the grace-period, or it was covered by other anticoagulants/antiplatelets
(DDD90 days’ grace-period). OAC underuse: no OAC prescription in 2008, or other
anticoagulants/antiplatelets did not cover the day (DDD-based90 days
grace-period). RESULTS: Data of 183,448 AF patients were included, mean age 73.2
years (SD: 10.97 years), 55.6% male. Their average CHADS2 was 2.8 (SD 1.58). Con-
sidering CI, OAC was recommendable for 54251 (29.6%; scenario 1)/83653 (45.6%;
scenario 2) of all patients. Between 28.1% and 31.8% of all days were OAC use days
whereas 43.0%-48.7% were OAC underuse days. Relative underuse rates did not
differ between the two CI scenarios. Older female patients with a high number of
co-morbidities had a greater OAC underuse probability. CONCLUSIONS: Our anal-
ysis shows that the OAC underuse problem in AF patients in the German health
care system is possibly more widespread than previous observational studies have
shown.
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OBJECTIVES: Assessment and comparison of baseline clinical characteristics, cur-
rent trend of utilization of key evidence-based-medications (EBM) and interven-
tional strategies for ACS patients presented with and without diabetes.METHODS:
This observational cohort study was conducted at The Heart Care Clinic, Ahmed-
abad among patients presented with ACS. In this cross-sectional study, data base
from the clinic was accessed to collect the data. This includes demographic infor-
mation, vital signs, personal particulars and details of other risk factors for ACS
such as diabetes, smoking and family history of coronary artery disease. Also in-
formation pertaining intervention procedure (medical management or percutane-
ous transluminal coronary angioplasty [PTCA] or coronary artery bypass grafting
[CABG]) and medications prescribed at discharge were collected. RESULTS: Among
370 ACS patients, about 30% patients were diabetic. Typically, percentage of hyper-
tensive patients was significantly higher among diabetics compared to non-diabet-
ics (59.29% vs. 38.91%, p0.0004). The difference in proportion of patients on med-
ical management among diabetic and non-diabetic patient population was found
to be highly significant (47.79% vs. 39.30%, p0.0002). Key medications (ACEIs/
ARBs, BBs, statins, and aspirin) were prescribed in 98.2, 85.0%, 87.6%, and 95.6%
diabetic (113); while 97.3%, 82.1%, 93.8%, and 96.5% non-diabetic (257) patients,
respectively on discharge. CONCLUSIONS:Diabetes is highly prevalent among ACS
patient population and the worse prognosis in ACS patients from India may be
attributed to clustering of several cardiovascular risk factors at presentation. The
diabetics are being managed more frequently with cardiovascular medications
rather than revascularization therapy (PTCA or CABG) compared to non-diabetics.
Utilization of evidence-based-medication for both diabetic and non-diabetic ACS is
consistent with the guidelines and recommendations and is not differing among
the diabetic and non-diabetic population; except for the lipid lowering therapy.
This observational study might serve as a maneuver to the current practice and
highlights awareness on the adherence to the recommendations from the guide-
lines.
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OBJECTIVES: To assess the prevalence and pattern of concomitant medication
(CM) use in US adults on statin therapy. METHODS: A retrospective analysis was
conducted using a large, US employer-based claims database. The study cohort
included adults 18 years old with 1 statin prescription between January 1, 2009
and December 31, 2009 with at least 6 months pre- and 3 months post-index (90-
day study period) continuous enrollment. CM use was defined as a drug, excluding
statins, recorded as prescribed to a patient. Data on the prevalence and pattern of
use of CMs, including CMs that potentially interact with statins, were analyzed.
Chi-square analyses were performed to examine relations between prevalence of
CM use (5 CM use vs. 5 CM use) and demographic variables (age groups and
gender). RESULTS: The study included 403,182 statin users, mean age 58 (SD 12)
years, 75% 65 years, and 52% male. Patients were prescribed an average of ap-
proximately 6 CMs during the study period. A total of 334,033 (83%) and 231,508
(57%) patients were prescribed 3 and 5 CMs. The proportion of patients pre-
scribed 5 CMs was significantly higher in females (63% vs. 52%, P0.0001) and
patients 65 years old (72% vs. 52%, P0.0001) compared to males and those 65
years old. Commonly prescribed CMs that potentially interact with statins included
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fenofibrates (4%), diltiazem hydrochloride (3%), niacin (2%), verapamil hydrochlo-
ride (1%), fluconazole (1%), gemfibrozil glucuronide (1%), amiodarone (1%), keto-
conazole (1%), and clarithromycin (1%). The proportion of patients prescribed with
CMs that potentially interact with statins was generally higher in patients with 5
CMs.CONCLUSIONS:The majority of statin users in this study were taking5 CMs.
Statin users with 5 CMs were more likely to be female and 65 years old. Use of
CMs that potentially interact with statins is not uncommon and more prevalent in
those using 5 CMs.
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OBJECTIVES: To evaluate the proportion of patients initiating statins achieving
NCEP ATP III low-density lipoprotein cholesterol (LDL-C) goals. METHODS: Adults
18 years of age, initiating statins (atorvastatin, rosuvastatin, simvastatin, prava-
statin, fluvastatin, or lovastatin) between January 1, 2009 through September 30,
2009 with no use of the index statin 3 months prior to initiation were identified via
retrospective physician survey/chart extraction. LDL-C goal attainment was eval-
uated based on: 1) LDL-C lab values extracted from patients’ medical charts at 6
weeks, 12 weeks, 6 months, and 12 months after statin initiation, and 2) physician’s
assessment. Secondary endpoints included the proportion of patients with HDL-C
40 mg/dL (male) and50 mg/dL (female), and non-HDL-C goal within 12 months.
Subgroup analyses were conducted among 4 different populations: patients with 1)
prior CHD; 2) diabetes without CHD; 3) other CHD risk equivalents excluding dia-
betes or CHD; and 4) multiple (3) concomitant medications. RESULTS: A cohort of
869 patients was identified with mean age of 52 years, mean baseline LDL-C of 162
mg/dL, HDL-C of 40mg/dL, and non-HDL-C of 206 mg/dL. The proportions of pa-
tients achieving LDL-C goal based on lab values were 38%, 59%, 66% and 74% at 6
weeks, 12 weeks, 6 months, and 12 months, and were similar based on physician
assessment. The proportion of patients with HDL-C 40 mg/dL (male) was 68%,
50 mg/dL (female) was 44%, and 68% of patients reached non-HDL-C goal. The
proportions of patients achieving LDL-C goal in subgroup populations were 22%,
41%, 52%, 63% in patients with CHD; 17%, 39%, 45%, 55% in patients with diabetes;
20%, 34%, 52%, 60% in patients with other CHD risk equivalents; and 26%, 48%, 60%,
70% in patients with multiple concomitant therapies. CONCLUSIONS: A low per-
centage of patients achieved LDL-C goal after 1 year; particularly in patients with
diabetes and other CHD risk equivalents.
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OBJECTIVES:Understand the factors associated with failing to achieve NCEP ATP III
low-density-lipoprotein cholesterol (LDL-C) goals. METHODS: Adults 18 years of
age, initiating statins (atorvastatin, rosuvastatin, simvastatin, pravastatin, fluva-
statin, or lovastatin) between 1/1/2009 through 9/30/2009 with no use of the index
statin 3 months prior to initiation were identified via retrospective physician sur-
vey/chart extraction. Risk factors associated with failing to achieve LDL-C goal
were identified using 1) direct physician assessment and 2) logistic regression anal-
ysis. Physician assessment was reported for all patients as well as 4 subgroups
(patients with CHD, type 2 diabetes without CHD, other CHD risk equivalents ex-
cluding diabetes, and multiple [3] concomitant therapies). RESULTS: A cohort of
869 patients was identified (mean age 52 years). Twenty-four percent of patients
were unable to achieve LDL-C goal within 1 year after statin initiation. Based on
physician assessment, 45% did not achieve LDL-C goal due to poor adherence to
statin therapy, 35% for lifestyle changes, 26% for no/slow improvement on statin
therapy, and 14% for adverse events (e.g., myalgia) with statin therapy. Reasons
(poor adherence to statin therapy, lifestyle changes, no/slow improvement, and
adverse events) for not achieving LDL-C goal differed among subgroups: CHD sub-
group 36%, 38%, 26%, 14%; diabetes subgroup 32%, 24%, 32%, 21%; other CHD risk
equivalents subgroup 39%, 29%, 50%, 18%; multiple concomitant therapies sub-
group 36%, 30%, 39%, 15%. The logistic regression model indicated index statin,
older age, non-adherence to statin, having diabetes or other CHD risk equivalents,
smoking, high baseline LDL-C, and low baseline HDL-C were significantly (P0.05)
associated with failing to achieve LDL-C goals. CONCLUSIONS: This retrospective
chart review identified poor adherence to statin therapy, underlying clinical con-
ditions (diabetes or other CHD risk equivalents), adverse events such as myalgia,
smoking, baseline high LDL-C, and low HDL-C as factors associated with failure to
achieve LDL-C goals.
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OBJECTIVES: The prevalence of dementia is growing considerately in the recent
years. Little is known about how dementia affects care patterns after discharge for
acute coronary syndromes. This study was designed to assess differences between
care patterns for ACS patients with and without dementia. METHODS: We con-
ducted a retrospective cohort study of 87298 patients hospitalized for ACS (1835
with dementia) from January 1, 2006 to December 31, 2007, based on a nationwide
population-based data under national health insurance system. Primary outcomes
were use of aspirin, beta-blocker, angiotensin-converting enzyme inhibitors (ACEI)
or angiotensin receptor blocker (ARB), statin, and clopidogrel within 365 days after
the first ACS event. Secondary outcomes were implementations of invasive proce-
dures. Age-matched cohort at 1:2 ratio (N5005) was identified to control for con-
founding variable age. Multivariate logistic regression was performed to examine
the relationships between the diagnosis of dementia in ACS patients and their care
patterns. RESULTS: ACS patients with dementia were less likely to receive aspirin
(adjusted odds ratio (OR), 0.71; 95% CI, 0.64-0.78, p0.001), beta-blocker (adjusted
OR, 0.68; 95% CI, 0.61-0.75, p0.001), ACEI or ARB (adjusted OR, 0.70; 95% CI, 0.64-
0.78, p0.001), statin (adjusted OR, 0.57; 95% CI, 0.50-0.64, p0.001), and clopidogrel
(adjusted OR, 0.84; 95% CI, 0.74-0.95, p0.007) after the first ACS event compared
with ACS patients without dementia. They were also less likely to underwent in-
vasive procedures such as percutaneous transluminal coronary angioplasty (PTCA)
(adjusted OR, 0.57; 95% CI, 0.51-0.64, p0.001), coronary artery bypass graft (CABG)
(adjusted OR, 0.31; 95% CI, 0.20-0.48, p0.001), and revascularization (adjusted OR,
0.52; 95% CI, 0.47-0.59, p0.001) during the first ACS event. Similar results were
found in the age-matched cohort. CONCLUSIONS: The presence of dementia was
associated with underutilization of evidence-based therapies in ACS patients. In-
fluence of suboptimal treatments in ACS patients with dementia should be further
evaluated.
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OBJECTIVES: New treatment modalities may improve health outcomes but are
usually associated with substantial cost and budget impact, thus limiting the num-
ber of patients that may benefit from them. An alternative is implementing a
substantially lower cost intervention to a much wider population, accepting infe-
rior per-patient outcomes. We examined whether this approach can provide better
outcomes under a pre-specified budget constraint.METHODS: We used the results
from the JUPITER trial (Justification for the Use of Statins in Prevention: An Inter-
vention Trial Evaluating Rosuvastatin) and the United-States target population as a
case study. The target population is estimated at 6,700,000 patients: women 60;
men50, with normal LDL but elevated high sensitive C Reactive Protein levels. We
built a model that can compare the outcomes on the entire intended-use popula-
tion, and compared three treatment alternatives: 1) Rosuvastatin for a limited
patient population, with the clinical effect reported in JUPITER; and 2) Lowest cost
statin for most patients, with 75% of the JUPITER effect per patient; and 3) Usual
care (do-nothing) as a baseline for cost and effectiveness. We used a budget con-
straint of $200M per year, which covers the lowest cost statin for 75% of the target
population, and used a 5-year horizon, during which a potential of 268,000 Cardio-
vascular adverse events could be prevented. RESULTS: The budget allows for 3% of
the target patient population to be treated with Rosuvastatin, which resulted in
prevention of 7229 cardiovascular events as compared to usual care. Using the
lowest-cost statin allows for 75% of the target patient population to be treated
results in preventing 118,555 cardiovascular events and is cost-saving compared to
usual care. CONCLUSIONS: Under budget constraints, using lowest-cost statins
enables a substantially larger market access to treatment, which according to our
model resulted in significantly better health outcomes for the intended-use popu-
lation.
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OBJECTIVES: To present Brazilian data on atrial fibrillation (AF) and perform a cost
analysis of events related to this disease. METHODS: AF is an important risk factor
for stroke and ischemic heart failure (HF) and death. It is estimated that in Brazil
there are around 1.5 million patients with AF and that this population is correlated
with the age pyramid. The prevalence of AF in the general population is estimated
between 0.4% and 1%, increasing substantially with age. Among the strokes 20%
are related to AF and 85% of these strokes are of ischemic origin and 15% of hem-
orrhagic origin. The stroke mortality in Brazil is 20.5 per 100,000. A panel of experts
examined the resources related to the treatment of events related to AF. The panel
was conducted through a questionnaire, where the experts listed all procedures,
tests, drugs and materials used in every event. Unit costs for drugs and material
were obtained from acquisition lists (BPS and SIMPRO magazine, respectively),
hospitalization, exam and procedure costs were extracted from a public reimburse-
ment database (SIGTAP). RESULTS: From the expert panel performed, the cost of
events were: fatal ischemic stroke (IS) 11,810BRL (7,398USD), non-fatal IS without
disability 2,812BRL (1,761USD), non-fatal IS with moderate disability 4,470BRL
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